Also known as: EGFR Gene Test« Back to test list
Mutations in the EGFR (epidermal growth factor receptor) gene can guide the choice of therapy in patients with non-small cell lung cancer (NSCLC). Clinically relevant mutations occur in exons 18, 19, 20 and 21 of the gene.
The presence of specific EGFR mutations in non-small cell lung cancer (NSCLC) indicates sensitivity or resistance to EGFR tyrosine kinase inhibitor therapies.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
The cobas EGFR Mutation Test is used to detect the presence of several different mutations in the EGFR gene.
This test is usually requested by an oncologist. If ordered by a pathologist, the Medicare rebate may still apply. Please use the specific request form (see link below).
Formalin fixed, paraffin-embedded tissue (FFPE) – 10 sections of 4 uM thickness, dried overnight at 37 degrees onto charged/coated slides.
Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-10). The request should be accompanied by a completed Somatic Mutation Test Request Form and a copy of the original histopathology report.